Pfizer Inc. (PFE)
|Net Income (ttm)||13.23B|
|Ex-Dividend Date||Nov 4, 2021|
|Day's Range||41.38 - 42.03|
|52-Week Range||32.74 - 51.86|
|Price Target||46.58 (+12.3%)|
|Est. Earnings Date||Nov 2, 2021|
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brand... [Read more...]
In 2020, Pfizer's revenue was $41.91 billion, an increase of 1.79% compared to the previous year's $41.17 billion. Earnings were $9.62 billion, a decrease of -40.91%.Financial Statements
According to 20 analysts, the average rating for Pfizer stock is "Hold." The 12-month stock price forecast is 46.58, which is an increase of 12.27% from the latest price.
It depends mainly on the number of breakthrough cases of COVID-19.
We're at a very delicate time in this pandemic: FDA advisory panel member
Dr. Ofer Levy, a voting member of the FDA vaccine advisory panel, joins Closing Bell to discuss the panel's decision to recommend a booster dose of Johnson & Johnson's Covid vaccine.
Pfizer Inc. (NYSE: PFE) shares have lagged the S&P 500 in 2021, generating a year-to-date total return of 16.6%. Pfizer has gotten plenty of headlines for its COVID-19 vaccine, but investors may be wond...
Pfizer's Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermat...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recomme...
Pfizer has expanded its mRNA program into a new area.
The bar could be lower for the FDA to authorize booster shots for J&J's COVID-19 vaccine.
The company disappointed last year, but things may be turning around.
Pfizer or Alcoa? #AskHalftime
The "Halftime Report" traders answer viewer questions in #AskHalftime.
Is (PFE) Outperforming Other Medical Stocks This Year?
Pfizer's Cibinqo snagged an approval in Japan to treat patients with eczema.
J&J recipients who were administered Moderna or Pfizer boosters showed significantly higher antibody counts compared to those who received a booster of the same vaccine.
Someone with a lot of money to spend (and possibly insider knowledge) has taken a bullish stance on Pfizer(NYSE:PFE). And retail traders should know.
Rare heart inflammation issues with Moderna's vaccine could work to Pfizer's advantage -- but only slightly.
Pfizer (PFE) closed at $42.06 in the latest trading session, marking a -0.92% move from the prior day.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pfizer might not be far behind Merck in launching a COVID-19 pill.
These seven top stocks are among my top picks for investors seeking exposure to companies with the ability to ride out market turmoil. The post 7 Top Stocks That Held Up Well During This Recent Market B...